Shire Strives To Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
Apr 4th 2008Drug InformationInfectious Diseases / Bacteria / Viruses
Shire Pharmaceuticals, the global biopharmaceutical company, announced the launch of On Track, an innovative program designed to improve adherence to disease management regimens among chronic kidney disease (CKD) Stage 5 patients with hyperphosphatemia (elevated levels of phosphorus in the blood).
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
